REGISTRATION FOR SCHEDULED CAPITAL MARKETS DAY
OSLO, NORWAY (27 November 2017) – As previously announced, NattoPharma is pleased to invite investors, media and others to a Capital Markets Day and business update to be held at KS Agenda, Haakon VII’s Gate 9, Oslo, Norway on December 5th 2017.
The event will start with registration and coffee at 09:30, and the presentation will start at 10:00, followed by a Q&A session directly therafter. Light lunch will be served when the Q&A session has been completed.
If you would like to attend NattoPharmas CMD and business update, please register by email to CFO Kjetil Ramsøy, kjetil.ramsoy@nattopharma.com, within 16:00 on December 4th 2017.
The presentation will be held in English and will be published at approximately 09:30 the same day.
For more information, please contact:
Kjetil Ramsøy,
CFO
e-mail: kjetil.ramsoy@nattopharma.com
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
This information is information that NattoPharma ASA (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above at 15:45 CET on November 27th, 2017.
# # #
About NattoPharma and MenaQ7®
NattoPharma ASA, based in Norway, is the world’s leader in vitamin K2 research and development. NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, the best documented, vitamin K2 as menaquinone-7 (MK-7) with guaranteed actives and stability, clinical substantiation, and international patents granted and pending, and now the new MenaQ7® Full Spectrum, which delivers menaquinones 6, 7, 8, and 9. The company has a multi-year research and development program to substantiate and discover the health benefits of vitamin K2 for applications in the marketplace for functional food and dietary supplements. With a global presence, the company established its North American subsidiary, NattoPharma USA, Inc., in Edison, NJ, and NattoPharma R&D Ltd. in Cyprus. For more information, visit www.nattopharma.com or www.menaq7.com.
Tags: